Navigation Links
Omeros Announces Clinical Development Programs for OMS103HP and OMS302
Date:5/19/2011

utcomes measure used in the successful Phase 2 meniscectomy trial.

OMS302 will be evaluated for safety and efficacy in patients undergoing intra-ocular lens replacement surgery. The trials will enroll both cataract surgery and refractive lens exchange patients. This clinical program will involve two randomized, double-blind, placebo-controlled, multicenter trials. The first trial will be conducted in North America and data are expected in the first half of 2012.  Omeros will initiate the second trial in Europe following discussions with regulators to ensure that data collected meet European expectations for marketing approval. The co-primary endpoints for these trials – maintenance of intraoperative pupil dilation (mydriasis) and reduction of postoperative pain – are the same as those achieved in the recently completed 221-patient Phase 2b trial.

Omeros' OMS103HP Program

OMS103HP is Omeros' PharmacoSurgery™ product candidate being developed for use during arthroscopic procedures, including partial meniscectomy surgery, and was designed to provide a multimodal approach to preemptively block the inflammatory cascade induced by arthroscopy. OMS103HP is a proprietary combination of anti-inflammatory/analgesic active pharmaceutical ingredients (APIs), each with well-known safety and pharmacologic profiles. Each of the APIs are components of generic, FDA-approved drugs that have been marketed in the United States as over-the-counter or prescription drug products for over 15 years and have established and well-characterized safety profiles.

In a Phase 2 clinical trial that evaluated OMS103HP in patients undergoing partial meniscectomy surgery, OMS103HP provided clinically meaningful and significantly greater efficacy than vehicle as measured by patient-reported functional scores using the Knee Injury and Osteoarthritis Outcome Score (KOOS), passive knee flexion and visual analog scale pain scores. The patient-
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Omeros Corporation Reports First Quarter 2011 Financial Results
2. Omeros Announces Expansion of Potential Indications for PDE7 Inhibitors
3. Omeros Announces Publication of MASP-2 Data in Proceedings of the National Academy of Sciences
4. Omeros Reports Outcome of Phase 3 Trials of OMS103HP
5. Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results
6. Omeros Unlocks Orphan GPCRs Linked to Pancreatic Cancer and Cognitive Disorders
7. Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo
8. Omeros Announces Publication of Data From Antifibrinolytic Program
9. Omeros Licenses Novel Antifibrinolytic Agents
10. Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy
11. Omeros to Host Conference Call Monday, October 25 at 4:00 p.m. ET To Provide Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 19, 2014  Newport Corporation (NASDAQ: ... has joined the company,s Board of Directors.  Dr. ... a director of Evans Analytical Group, a leading ... analytical services to companies in a wide range ... Evans Analytical Group, Dr. Kadia spent nine years ...
(Date:12/19/2014)... 2014 Breckenridge Pharmaceutical, Inc. announced today that ... Laboratories Pvt. Ltd. ( Hyderabad, India ) ... new ANDAs.  Under the terms of the agreement, MSN ... Breckenridge for the U.S. market, and Breckenridge will market ... MSN have agreed to develop an oral antibiotic with ...
(Date:12/19/2014)... , Dec. 19, 2014 In ... research and marketing communication tools are essential for ... competitive – consequently consumers, desires, preferences, and unmet ... environment, market research groups across all industries are ... communication tools. However, the adoption of new market ...
Breaking Medicine Technology:Siddhartha Kadia, Ph.D. Joins Board of Directors of Newport Corporation 2Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with MSN Laboratories Pvt. Ltd. 2Study Uncovers New Tools and Techniques for Understanding Consumer Decision Making 2
... SKILLMAN, N.J., Feb. 7, 2011 ConvaTec, a world-leading ... and hospital care, today announced the appointment of several ... Nino Pionati has been appointed President, Intercontinental in ... Latin America and Canada. These markets continue to be ...
... 2011 BioSpecifics Technologies Corp. (Nasdaq: BSTC ... first in class collagenase-based products, today announced that its ... "Rights Agreement"), adopted May 14, 2002 and previously amended ... increases the ownership threshold for determining "Acquiring Person" status ...
Cached Medicine Technology:ConvaTec Announces New Appointments to Leadership Team 2
(Date:12/20/2014)... 20, 2014 Today, Balfleet.com, one of ... Christmas Sale, offering 50%-70% off on its Mother ... , The mother of the bride dresses from Balfleet.com ... is 24/7 accessible and takes pride in providing high ... “We are offering great discounts on our mother of ...
(Date:12/19/2014)... It’s very easy to become overwhelmed with the holidays ... the wayside until Christmas and the New Year are over. ... that burning desire to just escape it all and get ... Telluride with a no-fuss, affordable package. Montrose Days Inn will ... and ensure that all accommodations are met. Plus, everyone has ...
(Date:12/19/2014)... Florida (PRWEB) December 19, 2014 Sub Zero ... to sponsor a blood drive Sunday the 28th from 2pm-6pm ... Road & Sawyer Road in Sarasota, FL. , Inquiries regarding ... thank you for participating in the donating process, Sub Zero ... free flash frozen, custom ice cream. , About Sub Zero ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 ... dedicated to developing educational events, tools and resources ... Rouxbe Cooking School , the world’s leading online ... prescription every human being needs: Culinary Rx. As ... cooking course, Culinary Rx, scheduled for debut spring ...
(Date:12/19/2014)... Santa Rosa, CA (PRWEB) December 19, 2014 ... 2x4 and 5x5 SuperClone Rooms. SuperCloset continues to offer ... grow solutions. Pair one of the new SuperClone Rooms ... truly professional, perpetual, and turnkey indoor hydroponic grow room ... cloner in the world, SuperCloset’s SuperPonic SuperCloner 50 ...
Breaking Medicine News(10 mins):Health News:Balfleet.com is Offering 50%-70% Off of its Mother of the Bride Dresses 2Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2Health News:Shark Tank’s Sub Zero Ice Cream Sponsors Blood Drive 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 3Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 4Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2
... Massachusetts General Hospital (MGH), together with a coalition of ... world,s largest registry of patients who have had optical ... an intravascular imaging technology that researchers hope will give ... plaques that cause heart attacks and sudden cardiac death. ...
... finds , THURSDAY, March 25 (HealthDay News) -- More than ... said that they drank alcohol in the past month, according ... The analysis of 2006-2008 data from the National Survey on ... rates were as high as 40 percent in some states, ...
... The effectiveness of ordinary surgical masks as opposed to ... H1N1 influenza virus has been the subject of debate. ... issue of Clinical Infectious Diseases, available online ... as effective as respirators in this regard. ...
... ... strategy to treat motor symptoms in rats with a disease designed to mimic Parkinson,s disease. ... San Francisco, CA (Vocus) ... symptoms in rats with a disease designed to mimic Parkinson,s disease., , , , ,The ...
... This press release is available in French . ... a previously hidden channel to attack leukemia and other cancer ... Journal of Biological Chemistry . The findings from the Universit ... way doctors treat cancer patients. "We found a gateway, ...
... survey finds , THURSDAY, March 25 (HealthDay News) ... likely to be chronically offline: they use the Internet ... , The survey, conducted by the Pew Internet & ... published online March 24, found that just 62 percent ...
Cached Medicine News:Health News:Mass. General Hospital to create registry for coronary optical coherence tomography 2Health News:Underage Drinking Soars in U.S. 2Health News:Novel Parkinson's Treatment Strategy Involves Cell Transplantation 2Health News:Novel Parkinson's Treatment Strategy Involves Cell Transplantation 3Health News:Novel Parkinson's Treatment Strategy Involves Cell Transplantation 4Health News:New gateway to treat leukemia and other cancers 2Health News:Chronic Disease Linked to Less Internet Usage 2
... NGAL (neutrophil gelatinase-associated lipocalin, lipocalin-2) is a ... predicting acute renal failure with a >90% ... especially in urine, as early as 2 ... an ideal diagnostic marker for acute renal ...
... quality control material used for monitoring the ... on CO-Oximeter instrumentation. It provides an alternative ... the human physiologic range for tHb, O2Hb, ... three (3) levels for monitoring analyzer performance ...
... 233 is an assayed quality ... the measurements of total hemoglobin ... instrumentation. It is available in ... analyzer performance at varying points ...
... QC 623 is an assayed quality control material ... available in four (4) levels for monitoring analyzer ... It may be used on multiple test analyzers ... the Radiometer 600). QC623 is also for use ...
Medicine Products: